The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis

European Journal of Clinical Pharmacology

Volumn 68, Issue 5, 2012, Pages 689-695

  Gengiah, Tanuja N ^a,c   Holford, Nicholas H G ^b   Botha, Julia H ^c   Gray, Andrew L ^a,c   Naidoo, Kogieleum ^a   Karim, Salim S Abdool ^a,d  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d Department of Medicine   (United States)

Author keywords

Efavirenz; HIV; Pharmacokinetics; Rifampicin; Tuberculosis

Indexed keywords

CYTOCHROME P450 2B6; DIDANOSINE; EFAVIRENZ; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ISONIAZID PLUS RIFAMPICIN; LAMIVUDINE; RIFAMPICIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG INHIBITION; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; TREATMENT DURATION; TUBERCULOSIS;

ADULT; ANTI-HIV AGENTS; ANTIBIOTICS, ANTITUBERCULAR; BENZOXAZINES; BIOTRANSFORMATION; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HIV INFECTIONS; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; REVERSE TRANSCRIPTASE INHIBITORS; RIFAMPIN; SOUTH AFRICA; TUBERCULOSIS; YOUNG ADULT;

EID: 84864287491     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1166-5     Document Type: Article

References (34)

1. World Health Organization (2008) Global tuberculosis control: surveillance planning financing. WHO, Geneva
2. Dean GL, Edwards SG, Ives NJ, Matthews G, Fox EF, Navaratne L, Fisher M, Taylor GP, Miller R, Taylor CB, de Ruiter A, Pozniak AL (2002) Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 16 (1):75-83 (Pubitemid 34062184)
3. Gengiah TN, Gray AL, Naidoo K, Karim QA (2011) Initiating antiretrovirals during tuberculosis treatment: a drug safety review. Expert Opin Drug Saf 10:559-574. doi:10.1517/14740338.2011.546783
4. Finch CK, Chrisman CR, Baciewicz AM, Self TH (2002) Rifampin and rifabutin drug interactions: an update. Arch Intern Med 162(9):985-992 (Pubitemid 34492526)
5. Desta Z, Soukhova NV, Flockhart DA (2001) Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother 45(2):382-392. doi:10.1128/AAC.45.2.382-392.2001 (Pubitemid 32105271)
6. Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH, Watkins PB (2002) Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 72(1):1-9. doi:10.1067/mcp.2002.124519 (Pubitemid 34833182)
7. Ogburn ET, Jones DR, Masters AR, Xu C, Guo Y, Desta Z (2010) Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab Dispos 38(7):1218-1229. doi:10.1124/dmd.109.031393
8. Smith PF, DiCenzo R, Morse GD (2001) Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 40(12):893-905 (Pubitemid 34066687)
9. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T (2001) Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15(1):71-75 (Pubitemid 32055781)
10. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Alarcon-Gonzalez A, Gomez-Mateos J, Leon-Jimenez E, Sarasanacenta M, Lopez-Pua Y, Pachon J (2002) Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 41(9):681-690
11. Matteelli A, Regazzi M, Villani P, De Iaco G, Cusato M, Carvalho AC, Caligaris S, Tomasoni L, Manfrin M, Capone S, Carosi G (2007) Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. Curr HIV Res 5(3):349-353 (Pubitemid 46785071)
12. Brennan-Benson P, Lyus R, Harrison T, Pakianathan M, Macallan D (2005) Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. AIDS 19(14):1541-1543 (Pubitemid 41400701)
13. Friedland G, Khoo S, Jack C, Lalloo U (2006) Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother 58(6):1299-1302. doi:10.1093/jac/dkl399 (Pubitemid 44884158)
14. Chi J, Jayewardene AL, Stone JA, Motoya T, Aweeka FT (2002) Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS. J Pharm Biomed Anal 30(3):675-684 (Pubitemid 35279694)
15. Beal SL SL, Boeckmann A. (1999) NONMEM user's guide. Division of Pharmacology, University of California, San Francisco
16. Csajka C, Marzolini C, Fattinger K, Decosterd LA, Fellay J, Telenti A, Biollaz J, Buclin T (2003) Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 73(1):20-30. doi:10.1067/mcp.2003.22 (Pubitemid 36158483)
17. Holford NH (1996) A size standard for pharmacokinetics. Clin Pharmacokinet 30(5):329-332 (Pubitemid 26177179)
18. Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Kumar P, Ramesh K, Anitha S, Narendran G, Menon P, Gomathi C, Swaminathan S (2009) CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. Antimicrob Agents Chemother 53 (3):863-868. doi:10.1128/AAC. 00899-08
19. Cabrera SE, Cordero M, Iglesias A, Valverde MP, Dominguez-Gil A, Garcia MJ (2008) Efavirenz-rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients. AIDS 22(18):2549-2551. doi:10.1097/QAD.0b013e3283189c07
20. Lopez-Cortes LF, Ruiz-Valderas R, Ruiz-Morales J, Leon E, de Campos AV, Marin-Niebla A, Marquez-Solero M, Lozano F, Valiente R (2006) Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen. J Antimicrob Chemother 58(5):1017-1023. doi:10.1093/jac/dkl357
21. Rekic D, Roshammar D, Mukonzo J, Ashton M (2011) In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. Br J Clin Pharmacol 71(4):536-543. doi:10.1111/j.1365-2125.2010. 03883.x
22. Ren Y, Nuttall JJ, Eley BS, Meyers TM, Smith PJ, Maartens G, McIlleron HM (2009) Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 50(5):439-443. doi:10.1097/QAI.0-b013e31819c33a3
23. Cohen K, Grant A, Dandara C, McIlleron H, Pemba L, Fielding K, Charalombous S, Churchyard G, Smith P, Maartens G (2009) Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516 G > T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 14 (5):687-695
24. Stohr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T, Ainsworth J, Pozniak A, Leen C, Bansi L, Fisher M, Orkin C, Anderson J, Johnson M, Easterbrook P, Gibbons S, Khoo S (2008) Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther 13(5):675-685
25. Kwara A, Lartey M, Sagoe KW, Xexemeku F, Kenu E, Oliver-Commey J, Boima V, Sagoe A, Boamah I, Greenblatt DJ, Court MH (2008) Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. J Clin Pharmacol 48(9):1032-1040. doi:10.1177/0091270008321790
26. Kwara A, Lartey M, Sagoe KW, Court MH (2011) Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. AIDS 25(3):388-390. doi:10.1097/QAD.0b013e3283427e05
27. Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer NH, Bogner JR, Rockstroh J, Esser S, Jaeger H, Harrer T, Mauss S, van Lunzen J, Skoetz N, Jetter A, Groneuer C, Fatkenheuer G, Khoo SH, Egan D, Back DJ, Owen A (2008) Impact of CYP2B6 983 T > C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother 61(4):914-918. doi:10.1093/jac/dkn029 (Pubitemid 351436194)
28. Mehlotra RK, Bockarie MJ, Zimmerman PA (2007) CYP2B6 983 T > C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment. Br J Clin Pharmacol 64(3):391-395. doi:10.1111/j.1365-2125.2007.02884.x (Pubitemid 47283857)
29. *6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 64(4):357-365. doi:10.1007/s00228-007-0412-3
30. *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br J Clin Pharmacol 67 (4):427-436. doi:10.1111/j.1365- 2125.2009.03368.x
31. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, Acosta EP (2004) Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18 (18):2391-2400 (Pubitemid 40065906)
32. Kappelhoff BS, Huitema AD, Yalvac Z, Prins JM, Mulder JW, Meenhorst PL, Beijnen JH (2005) Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin Pharmacokinet 44(8):849-861 (Pubitemid 41126932)
33. Barrett JS, Joshi AS, Chai M, Ludden TM, Fiske WD, Pieniaszek HJ Jr (2002) Population pharmacokinetic meta-analysis with efavirenz. Int J Clin Pharmacol Ther 40 (11):507-519 (Pubitemid 35331935)
34. Pfister M, Labbe L, Hammer SM, Mellors J, Bennett KK, Rosenkranz S, Sheiner LB (2003) Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother 47(1):130-137 (Pubitemid 36070353)